Federal Register / Vol. 62, No. 73 / Wednesday, April 16, 1997 / Notices 18631

1 In 1977, the Commission reaffirmed its thencurrent policy of maintaining the confidentiality of

most nonpublic investigations. See FTC Policy

statement, 42 Fed. Reg. 64,135 (Dec. 22, 1977)

(‘‘1977 Policy Statement’’). This Policy Statement

sets forth exceptions for industrywide

investigations and investigations involving

‘‘significant risk of economic harm or risk to public

health or safety.’’ In addition, certain investigations

may become public by operation of law or the

Commission’s Rules, for example, on filing of a

petition to quash compulsory process, 16 C.F.R.

§ 4.9(b)(4), on filing of an application for clearance,

16 C.F.R. § 4.9(10(ii), or on publication in the

Federal Register of a notice of early termination

under the Clayton Act, 15 U.S.C. § 18a(b)(2).

2 Id. See also Exemption 7A to the mandatory

public disclosure requirements of the Freedom of

Information Act, 5 U.S.C. § 552(b)(7)(A); and

Exemption 7A to the open meeting requirements of

the Government in the Sunshine Act, 5 U.S.C.

§ 552b(c)(7)(A).

3See note 1.

in the policy) by third parties. The

policy also enables the commission to

confirm certain nonpublic information

that has not been confirmed by third

parties. Under the new policy, the

Commission will confirm the fact that it

is investigating a transaction after the

transaction itself has been made public

and regardless of whether the fact of the

investigation has been made public by

third parties.

The Commission long has followed a

policy of declining to confirm the

existence of its investigations until it

issues or authorizes filing of a

complaint, or until the matter is closed.1

This policy is based on the premise that

public disclosure of pending

investigations and identification of

targets can interfere with the conduct

and successful resolution of such

matters.2 The Commission concluded in

the 1977 Policy Statement that

‘‘disclosure of the identities of

businesses under investigation would

cause those businesses severe economic

injury even before the Commission

determines whether there is reason to

believe the law has been violated.’’

I have been informed that the

business community will have no

objection to having the Commission

confirm the fact that it is investigating

a transaction even if the parties have not

confirmed the fact of the investigation.

I do not know the basis for this

information. Assuming the information

is correct, I support the new policy in

its entity because the policy presumably

would not result in the harm the

Commission identified in 1977.3

Nevertheless, I would have preferred to

seek comment on this aspect of the new

policy before adopting it. Good reasons

support the Commission’s long standing

policy not to confirm or deny the

existence of a nonpublic investigation,

and the Commission has been able to

live with that policy for many years. It

seems appropriate and not unduly

burdensome for the Commission to seek

public comment on this aspect of the

proposal for thirty days before adopting

it. To the extent that the Commission

has chosen not to seek public comment,

I dissent.

[FR Doc. 97–9820 Filed 4–15–97; 8:45 am]

BILLING CODE 6750–01–M

GENERAL SERVICES

ADMINISTRATION

Federal Acquisition Policy Division,

FAR Secretariat; Cancellation of

Standard Forms

AGENCY: General Services

Administration.

ACTION: Notice.

SUMMARY: Since 48 CFR 52.215–41 and

42 give agencies more flexible

procedures in requesting exceptions for

submitting certified cost and pricing

data, the following Standard Forms are

canceled:

SF 1412, Request For Exemption From

Submission Of Certified Cost Or Pricing Data.

SF 1412A, Request For Exemption From

Submission Of Certified Cost Or Pricing

Data—Continuation.

DATES: Effective April 16, 1997.

FOR FURTHER INFORMATION CONTACT:

Ms. Barbara Williams, General Services

Administration, (202) 501–0581.

Dated: March 19, 1997.

Barbara M. Williams,

Deputy Standard and Optional Forms

Management Officer.

[FR Doc. 97–9754 Filed 4–15–97; 8:45 am]

BILLING CODE 6820–34–M

GENERAL SERVICES

ADMINISTRATION

Interagency Committee for Medical

Records (ICMR); Revision of SF 93,

Medical Record—Report of Medical

History

AGENCY: General Services

Administration.

ACTION: Notice.

SUMMARY: The General Services

Administration/ICMR is revising the SF

93, Medical Record—Report of Medical

History to update the information

collected on the patient. You can obtain

the updated form in three ways:

From the ‘‘U.S. Government Management

Policy CD–ROM’’;

On the internet. Address: http://

www.gsa.gov/forms, or;

Through the Federal Supply Service using

National Stock Number 7540–00–181–8368

(revision 6–96).

FOR FURTHER INFORMATION CONTACT:

Ms. Barbara Williams, General Services

Administration, (202) 501–0581.

DATES: Effective April 16, 1997.

Dated: March 20, 1997.

Barbara M. Williams,

Deputy Standard and Optional Forms

Management Officer.

[FR Doc. 97–9753 Filed 4–15–97; 8:45 am]

BILLING CODE 6820–34–M

GENERAL SERVICES

ADMINISTRATION

Real Estate Management; Cancellation

of a Standard Form

AGENCY: Public Building Service,

General Services Administration.

ACTION: Notice.

SUMMARY: This notice announces the

General Services Administration’s

intent to cancel the following Standard

form because of low user demand: SF

2B, U.S. Government Lease for Real

Property (Short Form).

This form was replaced with GSA

Form 3626, U.S. Government Lease for

Real Property (Short Form). You can get

copies of this form from the contact

person mentioned below or from the

following internet address: http://

www.gsa/gov/pbs/pe/standcla/

standcla.htm.

FOR FURTHER INFORMATION CONTACT:

Mr. Gary Roberts, Real Estate

Management Division, Office of

Property Acquisition and Realty

Services, (202) 501–0407.

DATES: Effective April 16, 1997.

Dated: March 7, 1997.

Theodore D. Freed,

Standard and Optional Forms Management

Officer.

[FR Doc. 97–9755 Filed 4–15–97; 8:45 am]

BILLING CODE 6820–34–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that

the Office of Research Integrity (ORI)

has made a final finding of scientific

misconduct in the following case:

Manoj Misra, Ph.D., Dartmouth

College: Based upon the Office of

Research Integrity’s (ORI) review of a

report forwarded to ORI by Dartmouth
18632 Federal Register / Vol. 62, No. 73 / Wednesday, April 16, 1997 / Notices

College, Dr. Misra’s admission of certain

facts in that report, and ORI’s own

analysis, ORI found that Dr. Misra, a

former postdoctoral research associate,

Department of Chemistry, Dartmouth

College, engaged in scientific

misconduct by intentionally altering

laboratory notebook data entries for

research supported by a grant from the

National Institute of Environmental

Health Sciences (NIEHS), National

Institutes of Health (NIH).

Specifically, Dr. Misra altered

laboratory notebook data entries in two

instances in an effort to conceal prior

manipulations of that data without

disclosure or explanation to the

principal investigator or anyone else.

The experiment at issue involved an

assay of the chemical activity of a

carcinogen, and Dr. Misra’s change in

the readings of the ‘‘control’’

experiment, in which no carcinogen was

present, changed the results.

Dr. Misra has accepted the ORI

finding and has entered into a Voluntary

Exclusion Agreement with ORI in which

he has voluntarily agreed, for the three

(3) year period beginning April 7, 1997:

(1) To exclude himself from serving in

any advisory capacity to the Public

Health Service (PHS), including but not

limited to service on any PHS advisory

committee, board, and/or peer review

committee, or as a consultant; and

(2) That any institution that submits

an application for PHS support for a

research project on which Dr. Misra’s

participation is proposed or which uses

him in any capacity on PHS supported

research must concurrently submit a

plan for supervision of his duties. The

supervisory plan must be designed to

ensure the scientific integrity of Dr.

Misra’s research contribution. The

institution must submit a copy of the

supervisory plan to ORI.

No scientific publications were

required to be corrected as part of this

Agreement.

FOR FURTHER INFORMATION CONTACT:

Acting Director, Division of Research

Investigations, Office of Research

Integrity, 5515 Security Lane, Suite 700,

Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–9733 Filed 4–15–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

National Vaccine Advisory Committee

(NVAC), Subcommittee on Vaccine

Safety, Subcommittee on Immunization

Coverage, Subcommittee on Future

Vaccines, and the Advisory

Commission on Childhood Vaccines

(ACCV) Subcommittee on Vaccine

Safety: Meetings

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following Federal

advisory committee meetings.

Name: National Vaccine Advisory

Committee (NVAC).

Times and dates: 8:45 a.m.–12:15 p.m.,

May 1, 1997. 8:30 a.m.–1:15 p.m., May 2,

1997.

Place: Hubert H. Humphrey Building,

Room 703A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Notice: In the interest of security, the

Department has instituted stringent

procedures for entrance to the Hubert H.

Humphrey Building by non-government

employees. Thus, persons without a

government identification card should plan

to arrive at the building each day either

between 8 and 8:30 a.m. or 12:30 and 1 p.m.

so they can be escorted to the meeting.

Entrance to the meeting at other times during

the day cannot be assured.

Purpose: This committee advises and

makes recommendations to the Director of

the National Vaccine Program on matters

related to the Program responsibilities.

Matters to be discussed: Agenda items will

include a National Vaccine Program Office

(NVPO) update; a discussion on review of the

Department of Health and Human Services’

Adult Immunization Plan; a discussion on

the survey on practices of non-traditional

providers; a report of meeting on simianvirus-40—next steps; AIDS vaccine, the

progress in vaccine development and

organizational approach; the national vaccine

plan focusing on priorities; tuberculosis

vaccines, barriers and opportunites; the

National Institutes of Health (NIH) will

discuss their program on tuberculosis and

vaccine options; discussion from the

Advisory Council on the Elimination of

Tuberculosis; improving immunization

coverage report from the Sabin Foundation;

report from the Subcommittee on

Immunization Coverage; report from the

Subcommittee on Future Vaccines; report

from the Subcommittee on Vaccine Safety;

and status of the Work Group on

philosophical exemptions.

Agenda items are subject to change as

priorities dictate.

Name: Subcommittee on Vaccine Safety

and the Advisory Commission on Childhood

Vaccines, Subcommittee on Vaccine Safety.

Time and date: 1:15 p.m.–5 p.m., May 1,

1997.

Place: Hubert H. Humphrey Building,

Room 425A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: This joint NVAC/ACCV

subcommittee will review issues relevant to

vaccine safety and adverse reactions to

vaccines.

Matters to be discussed: This

subcommittee will discuss the update on the

Public Health Service vaccine safety

activities; vaccine safety surveillance

overview; vaccine safety funding; and agenda

items for next meeting.

Name: Subcommittee on Immunization

Coverage.

Time and date: 1:15 p.m.–5 p.m., May 1,

1997.

Place: Hubert H. Humphrey Building,

Room 423A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: This subcommittee will identify

and propose solutions that provide a

multifaceted and holistic approach to

reducing barriers that result in low

immunization coverage for children.

Matters to be discussed: This

subcommittee will discuss the review of

recommendations from the document

‘‘Strategies to Sustain Immunization

Coverage’; and a discussion and finalization

of the recommendations.

Name: Subcommittee on Future Vaccines.

Time and date: 1:15 p.m.–5 p.m., May 1,

1997.

Place: Hubert H. Humphrey Building,

Room 405A, 200 Independence Avenue, SW,

Washington, DC 20201.

Status: Open to the public, limited only by

the space available.

Purpose: The Subcommittee on Future

Vaccines will develop policy options and

guide national activities which will lead to

accelerated development, licensure, and best

use of new vaccines in the simplest possible

immunization schedules.

Matters to be discussed: This

subcommittee will discuss an update on

vaccine procurement strategies and case

studies in vaccine development.

Contact person for more information:

Felecia D. Pearson, Committee Management

Specialist, NVPO, CDC, 1600 Clifton Road,

NE, M/S D50, Atlanta, Georgia 30333,

telephone 404/639–7250.

Dated: April 11, 1997.

John C. Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–9902 Filed 4–15–97; 8:45 am]

BILLING CODE 4163–18–P